Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Summaries of opinion Remove Summaries of opinion filter Paediatric investigation plans Remove Paediatric investigation plans filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Withdrawn applications (9) Apply Withdrawn applications filter Orphan designations (121) Apply Orphan designations filter Referrals (16) Apply Referrals filter

Product number

Patient safety

Yes (10) Apply Yes filter

Authorisation status

Authorised (342) Apply Authorised filter Refused (1) Apply Refused filter Withdrawn (42) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Opinion status

Positive (14) Apply Positive filter

Application type

Initial authorisation (1) Apply Initial authorisation filter Post-authorisation (13) Apply Post-authorisation filter

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (14) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (130) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (1) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter W: decision granting a waiver in all age groups for all conditions or indications (29) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (13) Apply Yes filter

Compliance procedure number

Medicine type

Additional monitoring Remove Additional monitoring filter Accelerated assessment (79) Apply Accelerated assessment filter Biosimilar (96) Apply Biosimilar filter Conditional approval (89) Apply Conditional approval filter Exceptional circumstances (60) Apply Exceptional circumstances filter Generic (297) Apply Generic filter Orphan medicine (271) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

608 results

Remove all filtersRemove all filters

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Summaries of opinion Remove Summaries of opinion filter Direct healthcare professional communication Remove Direct healthcare professional communication filter

Categories Human Remove Human filter

Medicine type Additional monitoring Remove Additional monitoring filter

Sort by

List item

Human medicine European public assessment report (EPAR): Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (updated)

ChAdOx1-SARS-COV-2, COVID-19 virus infection
Date of authorisation: 29/01/2021, , , Revision: 27, Authorised, Last updated: 20/03/2023
List item

Human medicine European public assessment report (EPAR): Erleada (updated)

apalutamide, Prostatic Neoplasms
Date of authorisation: 14/01/2019, , Revision: 9, Authorised, Last updated: 20/03/2023
List item

Human medicine European public assessment report (EPAR): Quviviq (updated)

daridorexant hydrochloride, Sleep Initiation and Maintenance Disorders
Date of authorisation: 29/04/2022, , Revision: 4, Authorised, Last updated: 17/03/2023
List item

Human medicine European public assessment report (EPAR): Evoltra (updated)

clofarabine, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 29/05/2006, , , Revision: 32, Authorised, Last updated: 17/03/2023
List item

Human medicine European public assessment report (EPAR): Livtencity (updated)

Maribavir, Cytomegalovirus Infections
Date of authorisation: 09/11/2022, , , Revision: 3, Authorised, Last updated: 17/03/2023
List item

Human medicine European public assessment report (EPAR): Zolgensma (updated)

onasemnogene abeparvovec, Muscular Atrophy, Spinal
Date of authorisation: 18/05/2020, , , , Revision: 10, Authorised, Last updated: 17/03/2023
List item

Human medicine European public assessment report (EPAR): Zabdeno (updated)

Recombinant Adenovirus type 26 (Ad26) encoding the glycoprotein (GP) of the Ebola virus Zaire (ZEBOV) Mayinga strain, Hemorrhagic Fever, Ebola
Date of authorisation: 01/07/2020, , , Revision: 3, Authorised, Last updated: 17/03/2023
List item

Human medicine European public assessment report (EPAR): Elzonris (updated)

tagraxofusp, Lymphoma
Date of authorisation: 07/01/2021, , , , Revision: 6, Authorised, Last updated: 15/03/2023
List item

Human medicine European public assessment report (EPAR): Ayvakyt (updated)

avapritinib, Gastrointestinal Stromal Tumors
Date of authorisation: 24/09/2020, , , , Revision: 6, Authorised, Last updated: 14/03/2023
List item

Human medicine European public assessment report (EPAR): Cablivi (updated)

Caplacizumab, Purpura, Thrombotic Thrombocytopenic
Date of authorisation: 30/08/2018, , , Revision: 7, Authorised, Last updated: 14/03/2023
List item

Human medicine European public assessment report (EPAR): Ebvallo (updated)

Tabelecleucel, Lymphoproliferative Disorders
Date of authorisation: 16/12/2022, , , , Revision: 2, Authorised, Last updated: 10/03/2023
List item

Human medicine European public assessment report (EPAR): Ronapreve (updated)

casirivimab, imdevimab, COVID-19 virus infection
Date of authorisation: 12/11/2021, , Revision: 3, Authorised, Last updated: 10/03/2023
List item

Human medicine European public assessment report (EPAR): Rizmoic (updated)

Naldemedine tosilate, Constipation
Date of authorisation: 18/02/2019, , Revision: 8, Authorised, Last updated: 09/03/2023
List item

Human medicine European public assessment report (EPAR): Fetcroja (updated)

cefiderocol sulfate tosilate, Gram-Negative Bacterial Infections
Date of authorisation: 23/04/2020, , Revision: 5, Authorised, Last updated: 08/03/2023
List item

Human medicine European public assessment report (EPAR): Senshio (updated)

ospemifene, Postmenopause
Date of authorisation: 14/01/2015, , Revision: 13, Authorised, Last updated: 08/03/2023
List item

Human medicine European public assessment report (EPAR): Mulpleo (previously Lusutrombopag Shionogi) (updated)

Lusutrombopag, Thrombocytopenia
Date of authorisation: 18/02/2019, , Revision: 8, Authorised, Last updated: 08/03/2023
List item

Human medicine European public assessment report (EPAR): Kauliv (updated)

teriparatide, Osteoporosis; Osteoporosis, Postmenopausal
Date of authorisation: 12/01/2023, , , Authorised, Last updated: 07/03/2023
List item

Human medicine European public assessment report (EPAR): Tecvayli (updated)

Teclistamab, Multiple Myeloma
Date of authorisation: 23/08/2022, , , Authorised, Last updated: 07/03/2023
List item

Human medicine European public assessment report (EPAR): Veyvondi (updated)

vonicog alfa, von Willebrand Diseases
Date of authorisation: 31/08/2018, , Revision: 6, Authorised, Last updated: 06/03/2023
List item

Human medicine European public assessment report (EPAR): Calquence (updated)

Acalabrutinib, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 05/11/2020, , Revision: 4, Authorised, Last updated: 06/03/2023
List item

Human medicine European public assessment report (EPAR): Mysimba (updated)

bupropion hydrochloride, naltrexone hydrochloride, Obesity; Overweight
Date of authorisation: 26/03/2015, , Revision: 24, Authorised, Last updated: 03/03/2023
List item

Human medicine European public assessment report (EPAR): Aimovig (updated)

erenumab, Migraine Disorders
Date of authorisation: 26/07/2018, , Revision: 9, Authorised, Last updated: 02/03/2023
List item

Human medicine European public assessment report (EPAR): Revlimid (updated)

lenalidomide, Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes
Date of authorisation: 14/06/2007, , Revision: 49, Authorised, Last updated: 02/03/2023
List item

Human medicine European public assessment report (EPAR): Pemazyre (updated)

pemigatinib, Cholangiocarcinoma
Date of authorisation: 26/03/2021, , , , Revision: 5, Authorised, Last updated: 02/03/2023
List item

Human medicine European public assessment report (EPAR): Imjudo (updated)

Tremelimumab, Carcinoma, Hepatocellular
Date of authorisation: 15/12/2022, , Authorised, Last updated: 02/03/2023